maccura(SZ:300463) Sou Hu Cai Jing·2025-06-17 08:57Core Viewpoint - The company, Maike Biological, has a high rolling price-to-earnings (PE) ratio of 239.19, significantly above the industry average of 49.80, indicating potential overvaluation in the market [1][3]. Company Summary - Maike Biological specializes in the research, production, sales, and related services of in vitro diagnostic products, with a wide range of testing reagents for various medical conditions [2]. - The latest financial report for Q1 2025 shows a revenue of 510 million yuan, a year-on-year decrease of 17.22%, and a net profit of 23.98 million yuan, down 80.09% from the previous year, with a gross profit margin of 56.76% [2]. Shareholder Information - As of March 31, 2025, the number of shareholders in Maike Biological is 35,022, a decrease of 1,242 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]. Industry Comparison - In the medical device industry, Maike Biological ranks 118th in terms of PE ratio, with the industry median at 36.84 and the average at 49.80 [1][3].